Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, shares his highlights from ASH 2021, including data on treatment-free remission and related clinical trial data within the field of chronic myeloid leukemia (CML). Dr Deininger additionally highlights advances made in molecular biology. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.